GoodRx vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 39)
GoodRx logo

GoodRx

EmergingHealthcare

Prescription Savings

NASDAQ-listed (GDRX) prescription savings platform comparing prices across 70K+ pharmacies; $750M revenue with stock under pressure from Amazon Pharmacy and Cost Plus Drugs competition.

AI VisibilityBeta
Overall Score
D39
Category Rank
#396 of 596
AI Consensus
90%
Trend
stable
Per Platform
ChatGPT
37
Perplexity
35
Gemini
39

About

GoodRx is a Santa Monica-based prescription savings and healthcare price comparison platform that enables consumers to compare prices, access discount coupons, and find the lowest-cost pharmacy for their prescriptions — providing free price comparison tools across 70,000+ US pharmacies and a GoodRx Gold subscription ($9.99/month) with even lower prices on 1,000+ common medications. Listed on NASDAQ (NASDAQ: GDRX), GoodRx went public in September 2020 and generates approximately $750 million in annual revenue primarily from pharmaceutical industry fees and consumer subscription revenue.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

39
Overall Score
81
#396
Category Rank
#17
90
AI Consensus
71
stable
Trend
stable
37
ChatGPT
80
35
Perplexity
75
39
Gemini
77
38
Claude
86
39
Grok
85

Key Details

Category
Prescription Savings
General
Tier
Emerging
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only GoodRx
Prescription Savings

Integrations

GoodRx is classified as company. Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.